EBS News and Press, Emergent Biosolutions Inc. From 04/01/21

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Eyes on a rare payrolls dayThe tech stock rally looks to keep going with Nasdaq futures solidly higher at the open, but the broader market is more cautions...

Human error led to the accidental mixing of vaccines at an Emergent BioSolutions (EBS) plant in Baltimore, rendering 15M doses of Johnson & Johnson's (JNJ) COVID-19 vaccine useless, The New York Times reports.Workers at the facility, which also manufactures AstraZeneca's (AZN) COVID-19 va...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this event. For further details see: Emergent Biosolutions (EBS) Presents At KeyBanc Life Sciences & MedTech Investor Forum - Slideshow

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this event. For further details see: Emergent Biosolutions (EBS) Presents At Global High Yiled & Leveraged Finance Virtual Conference - Slideshow

Tens of millions of doses of AstraZeneca's (AZN) COVID-19 vaccine are sitting in U.S. facilities as the company has not yet finished its U.S. clinical trial and has yet to apply for Emergency Use Authorization from the FDA, The New York Times reports.Given that many countries have authorized ...

A previously announced event with President Biden on Wednesday to celebrate Johnson & Johnson (JNJ) and Merck's (MRK) agreement to have the latter produce J&J's COVID-19 vaccine has been moved from Baltimore to the White House, Bloomberg reports.The event was slated to take place at a...

In an investigative article, the New York Times reveals how Emergent BioSolutions ([[EBS]] -1.2%) profited from selling anthrax vaccines to the government while the pandemic was raging across the country.The paper alleges that the financial interests of a few biotech firms...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this event. For further details see: Emergent BioSolutions (EBS) Presents At J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference - Slideshow

Mabion, a Polish biotechnology company has partnered with Novavax (NVAX) in a framework agreement that will pave the way for a potential manufacturing contract with the U.S.-based company for its COVID-19 vaccine candidate.Per the terms of the agreement, Mabion will initiate the pro...

Emergent Biosolutions ([[EBS]] -10.9%) managed to beat consensus estimates in Q4 2020 with the quarterly and yearly revenue rising ~61.8% and ~40.6% YoY, respectively.The revenue from the contract development and manufacturing services, which made up ~29.0% of the 2020 top-line...